A pan-cancer proteomic perspective on the cancer genome atlas

Nature Communications

Volumn 5, Issue , 2014, Pages

  Akbani, Rehan ^a   Ng, Patrick Kwok Shing ^a   Werner, Henrica M J ^a,b   Shahmoradgoli, Maria ^a   Zhang, Fan ^a   Ju, Zhenlin ^a   Liu, Wenbin ^a   Yang, Ji Yeon ^a,c   Yoshihara, Kosuke ^a   Li, Jun ^a   Ling, Shiyun ^a   Seviour, Elena G ^a   Ram, Prahlad T ^a   Minna, John D ^d   Diao, Lixia ^a   Tong, Pan ^a   Heymach, John V ^a   Hill, Steven M ^e   Dondelinger, Frank ^e   Städler, Nicolas ^e,f   Byers, Lauren A ^a   Meric Bernstam, Funda ^a   Weinstein, John N ^a   Broom, Bradley M ^a   Verhaak, Roeland G W ^a   Liang, Han ^a   Mukherjee, Sach ^e,g   Lu, Yiling ^a   Mills, Gordon B ^a   more..

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF BERGEN   (Norway)

^c Kumoh National Institute of Technology   (South Korea)

^d UNIVERSITY OF TEXAS AT DALLAS   (United States)

^e MRC BIOSTATISTICS UNIT   (United Kingdom)

^f NETHERLANDS CANCER INSTITUTE   (Netherlands)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PAN CANCER PROTEIN; PROTEIN; PROTEIN BCL 2; UNCLASSIFIED DRUG; UVOMORULIN; ERBB2 PROTEIN, HUMAN; MESSENGER RNA; TUMOR PROTEIN;

BIOMARKER; CANCER; GENE EXPRESSION; GENETIC VARIATION; GENOME; PROTEOMICS;

APOPTOSIS; ARTICLE; BASAL LIKE BREAST CANCER; BLADDER CANCER; BREAST CANCER; CANCER GENOME; CANCER PROGNOSIS; CANCER SURVIVAL; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; ENDOMETRIUM CANCER; GENE DOSAGE; GENOME; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN MICROARRAY; PROTEOMICS; RECTUM CANCER; REVERSE PHASE PROTEIN ARRAY; ANTIBODY SPECIFICITY; CLUSTER ANALYSIS; GENETICS; HUMAN GENOME; METABOLISM; NEOPLASM; NONPARAMETRIC TEST; SIGNAL TRANSDUCTION;

CLUSTER ANALYSIS; GENE DOSAGE; GENOME, HUMAN; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; ORGAN SPECIFICITY; PROTEOMICS; RECEPTOR, ERBB-2; RNA, MESSENGER; SIGNAL TRANSDUCTION; STATISTICS, NONPARAMETRIC;

EID: 84901814887     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms4887     Document Type: Article

References (68)

1. Myhre, S. et al. Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins. Mol. Oncol. 7, 704-718 (2013).
2. Park, E. S. et al. Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol. Cancer Ther. 9, 257-267 (2010).
3. Shankavaram, U. T. et al. Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol. Cancer Ther. 6, 820-832 (2007). (Pubitemid 46554552)
4. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
5. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
6. Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
7. Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011).
8. Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519-525 (2012).
9. Cancer Genome Atlas Research N. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43-49 (2013).
10. Cancer Genome Atlas Research N et al. Integrated genomic characterization of endometrial carcinoma. Nature 497, 67-73 (2013).
11. Li, J. et al. TCPA: a resource for cancer functional proteomics data. Nat. Methods 10, 1046-1047 (2013).
12. Payne, S. J., Bowen, R. L., Jones, J. L. &Wells, C. A. Predictive markers in breast cancer-the present. Histopathology 52, 82-90 (2008). (Pubitemid 350265187)
13. Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumour subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869-10874 (2001). (Pubitemid 32878711)
14. Cardnell, R. J. et al. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin. Cancer Res. 19, 6322-6328 (2013).
15. Awaya, H., Takeshima, Y., Furonaka, O., Kohno, N. & Inai, K. Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung. J. Clin. Pathol. 58, 1076-1080 (2005). (Pubitemid 41416058)
16. Blok, E. J., Kuppen, P. J., van Leeuwen, J. E. & Sier, C. F. Cytoplasmic overexpression of HER2: a key factor in colorectal cancer. Clin. Med. Insight Oncol. 7, 41-51 (2013).
17. Caner, V. et al. No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas. Pathol. Oncol. Res. 14, 261-266 (2008).
18. Fleischmann, A., Rotzer, D., Seiler, R., Studer, U. E. & Thalmann, G. N. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur. Urol. 60, 350-357 (2011).
19. Grob, T. J. et al. Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung. Modern Pathol. 25, 1566-1573 (2012).
20. Slomovitz, B. M. et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J. Clin. Oncol. 22, 3126-3132 (2004). (Pubitemid 41103726)
21. Cuadros, M. & Villegas, R. Systematic review of HER2 breast cancer testing. Appl. Immunohistochem. Mol. Morphology 17, 1-7 (2009).
22. Grimm, E. E., Schmidt, R. A., Swanson, P. E., Dintzis, S. M. & Allison, K. H. Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases. Am. J. Clin. Pathol. 134, 284-292 (2010).
23. Press, M. F. et al. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin. Cancer Res. 14, 7861-7870 (2008).
24. Yaziji, H. et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291, 1972-1977 (2004). (Pubitemid 38544278)
25. Barginear, M. F., John, V. & Budman, D. R. Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer. Mol. Med. 18, 1473-1479 (2012).
26. Hurvitz, S. A. et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J. Clin. Oncol. 31, 1157-1163 (2013).
27. Fleming, G. F. et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 116, 15-20 (2010).
28. Hoadley, K.A. et al. Multi-platform integration of 12 cancer types reveals cellof- origin classes with distinct molecular signatures. Cell. (In press) (2014).
29. Yao, M. et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J. Natl Cancer Inst. 94, 1569-1575 (2002). (Pubitemid 35277281)
30. Vivanco, I. et al. Differential sensitivity of glioma-versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2, 458-471 (2012).
31. Bacolod, M. D. & Barany, F. Molecular profiling of colon tumors: the search for clinically relevant biomarkers of progression, prognosis, therapeutics, and predisposition. Ann. Surg. Oncol. 18, 3694-3700 (2011).
32. Imamura, Y. et al. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin. Cancer Res. 18, 4753-4763 (2012).
33. Malhotra, P. et al. Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians. Tumour Biol. 34, 1901-1911 (2013).
34. Bremnes, R. M. et al. High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in nonsmall- cell lung cancer. J. Clin. Oncol. 20, 2417-2428 (2002). (Pubitemid 34525727)
35. Zhang, H. et al. Clinical significance of E-cadherin, beta-catenin, vimentin and S100A4 expression in completely resected squamous cell lung carcinoma. J. Clin. Pathol. 66, 937-945 (2013).
36. Laplante, M. & Sabatini, D. M. mTOR signaling in growth control and disease. Cell 149, 274-293 (2012).
37. Hodgson, M. C. et al. Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res. 71, 572-582 (2011).
38. Liu, S. et al. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell 15, 539-550 (2009).
39. Prat, A. et al. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist 18, 123-133 (2013).
40. Cheung, L. W. et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov. 1, 170-185 (2011).
41. Salvesen, H. B., Haldorsen, I. S. & Trovik, J. Markers for individualised therapy in endometrial carcinoma. Lancet. Oncol. 13, e353-e361 (2012).
42. Slomovitz, B. M. & Coleman, R. L. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin. Cancer Res. 18, 5856-5864 (2012).
43. Horiuchi, D. et al. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J. Exp. Med. 209, 679-696 (2012).
44. Yuan, Y. et al. Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nat. Biotechnol. Accepted (2014).
45. Daniels, T. R., Delgado, T., Helguera, G. & Penichet, M. L. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin. Immunol. 121, 159-176 (2006). (Pubitemid 44572972)
46. Friedman, J., Hastie, T. & Tibshirani, R. Sparse inverse covariance estimation with the graphical lasso. Biostatistics 9, 432-441 (2008). (Pubitemid 351882084)
47. Rue, H. & Held, L. Gaussian Markov Random Fields: Theory and Applications Monographs on statistics and applied probability Hiard Rue and Leonhard Held Chapman and Hall/CRC 2005 ISBN-10: 1-58488-432-0 (2005).
48. Chagpar, R. B. et al. Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase. Proc. Natl Acad. Sci. USA 107, 5471-5476 (2010).
49. Memmott, R. M. & Akt-dependent, Dennis PA. and -independent mechanisms of mTOR regulation in cancer. Cell Signal. 21, 656-664 (2009).
50. Serra, V. et al. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J. Clin. Invest. 123, 2551-2563 (2013).
51. Shaw, R. J. & Cantley, L. C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441, 424-430 (2006). (Pubitemid 44050136)
52. Canel, M. et al. Overexpression of focal adhesion kinase in head and neck squamous cell carcinoma is independent of fak gene copy number. Clin. Cancer Res. 12, 3272-3279 (2006).
53. Myllykangas, S. et al. Integrated gene copy number and expression microarray analysis of gastric cancer highlights potential target genes. Int. J. Cancer 123, 817-825 (2008). (Pubitemid 352032407)
54. Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P. & Pandolfi, P. P. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121, 179-193 (2005). (Pubitemid 40546387)
55. Smyth, G. K. Limma: linear models for microarray data. In 'Bioinformatics and Computational Biology Solutions using R and Bioconductor' (Springer, 2005).
56. Robnik-Sikonja, M. & Savicky, P. CORElearn: CORElearn-classification, regression, feature evaluation and ordinal evaluation. R package version 0.9.41. (2013).
57. Uhlen, M. et al. Towards a knowledge-based Human Protein Atlas. Nat. Biotechnol. 28, 1248-1250 (2010).
58. Hall, M. et al. The WEKA data mining software: an update. SIGKDD Explorations 11, 10-18 (2009).
59. Eisen, M. B., Spellman, P. T., Brown, P. O. & Botstein, D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl Acad. Sci. USA 95, 14863-14868 (1998). (Pubitemid 29003722)
60. Hartigan, J. A. Clustering Algorithms (John Wiley & Sons, 1975).
61. Broom, B. NGCHM: Utilities for creating Next Generation Clustered Heat Maps. R package version 0.5.1. (2013).
62. Neeley, E. S., Kornblau, S. M., Coombes, K. R. & Baggerly, K. A. Variable slope normalization of reverse phase protein arrays. Bioinformatics 25, 1384-1389 (2009).
63. Hennessy, B. T. et al. A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers. Clin. Proteomics 6, 129-151 (2010).
64. Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413-421 (2012).
65. Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612 (2013).
66. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. Royal Stat. Soc. Series 57, 12 (1995).
67. Coombes, K. R. ClassDiscovery: Classes and methods for 'class discovery' with microarrays or proteomics. R package version 2.13.4. (2012).
68. Zhao, T., Iu, H., Roeder, K., Lafferty, J. & Wasserman, L. The huge Package for high-dimensional undirected graph estimation in R. J. Machine Learning Res. 13, 4 (2012).